Barzolvolimab Misses Atopic Dermatitis Endpoints

Celldex reported November 19 that Phase 2 barzolvolimab did not significantly improve peak itch versus placebo in moderate-to-severe atopic dermatitis. The result challenges mast-cell depletion as a sufficient intervention in this population, while leaving…




